comparemela.com

Page 2 - Larimar Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Larimar Therapeutics (NASDAQ:LRMR) Receives Market Outperform Rating from JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Larimar Therapeutics (NASDAQ:LRMR – Free Report) in a report released on Tuesday, Benzinga reports. They currently have a $25.00 price objective on the stock. Several other brokerages also recently commented on LRMR. Citigroup increased their price objective on Larimar Therapeutics from $4.50 to $10.00 and […]

Leerink partnrsEntrypoint capitalLarimar therapeutics incVirtu financialSg americas securitiesLarimar therapeutics company profileFred alger managementLarimar therapeuticsFree reportLifesci capitalGet free reportFire capitalPoint capitalAlger managementLarimar therapeutics daily

Larimar Therapeutics (NASDAQ:LRMR) Sees Unusually-High Trading Volume on Analyst Upgrade

Larimar Therapeutics (NASDAQ:LRMR) Sees Unusually-High Trading Volume on Analyst Upgrade
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Leerink partnrsFred alger managementLarimar therapeutics company profileSg americas securitiesLarimar therapeutics incLarimar therapeuticsGet free reportLifesci capitalFire capitalAlger managementCapital partnersLarimar therapeutics daily

Larimar Therapeutics (NASDAQ:LRMR) Sees Unusually-High Trading Volume

Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) shares saw strong trading volume on Wednesday . 630,361 shares changed hands during mid-day trading, an increase of 18% from the previous session’s volume of 535,874 shares.The stock last traded at $8.50 and had previously closed at $7.89. Analyst Ratings Changes LRMR has been the subject of […]

Leerink partnrsVanguard group incLarimar therapeutics incVirtu financialJanus henderson groupEntrypoint capitalLarimar therapeuticsGet free reportHenderson groupPoint capitalVanguard groupLarimar therapeutics daily

Larimar Therapeutics Shares Up 22%, FDA Lifts Hold for Nervous System Disorder Treatment

Larimar Therapeutics Shares Up 22%, FDA Lifts Hold for Nervous System Disorder Treatment
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

Stephen nakrosisDow jones company incDrug administrationLarimar therapeuticsDow jones

Larimar Therapeutics Friedreich s Ataxia Investigational Drug Differentiated From Biogen s Marketed Drug - Larimar Therapeutics (NASDAQ:LRMR)

Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data from Phase 2 study shows well-tolerated treatment with significant frataxin level increases.

William blairBiogen incLarimar therapeutics

vimarsana © 2020. All Rights Reserved.